LIXT Lixte Biotechnology Holdings

Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer

Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer

EAST SETAUKET, NY, July 21, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. () today announced the appointment of Dr. James Miser as its Chief Medical Officer commencing August 1, 2020.

Dr. John S. Kovach, founder and CEO of Lixte, commented, “We are thrilled to welcome Jim Miser to our management team as we expand proof-of-principle clinical trials of our novel lead compound, LB-100. Dr. Miser is an expert in the design and monitoring of studies of new investigational agents seeking to establish evidence of improved efficacy as efficiently as possible while assuring maximum safety of patients needing better therapeutic options. In addition to his extensive clinical expertise, Dr. Miser adds a wealth of administrative experience gained in leadership roles at major cancer research centers.”

Dr. Miser is a pediatric hematologist/oncologist, internationally recognized as an expert in the study and treatment of childhood cancers. His outstanding career includes positions of major responsibility at: Seattle Children’s Hospital and City of Hope National Medical Center, where he served as President, Chief Executive Officer and Chief Medical Officer. Most recently, Dr. Miser has been dividing his time between serving as a member of the Active Staff in the Department of Pediatrics at City of Hope and being Chair Professor, College of Medical Sciences and Technology, Taipei Medical University, Taipei, Taiwan.

Dr. Miser has extensive experience in the clinical development of new anticancer drugs for pediatric malignancies, leading many clinical trials at institutional and national cancer study groups. He was a member of the Soft Tissue Sarcoma Strategy Group, and Member of the New Agents Executive and Steering Committee, Phase II Coordinator Children’s Cancer Group and Chairman, Data Monitoring Committee, National Wilms Tumor Society. He has authored more than 100 peer reviewed articles dealing primarily with pediatric clinical cancer studies.

About Lixte Biotechnology Holdings, Inc.

 is a biotech company that identifies enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Lixte's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or X-ray and immune checkpoint blockers.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at .

Additional information on the Company is available at .

Lixte Contact:



(631) 830-7092

EN
21/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lixte Biotechnology Holdings

 PRESS RELEASE

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells F...

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE’s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- . (“LIXTE” or the “Company”) ( and LIXTW), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether “initiated” cells that carry mutations found in...

 PRESS RELEASE

LIXTE Biotechnology Provides Update On Progress with Proprietary Compo...

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer -Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100's Potential in Enhancing Cancer Immunotherapies- -Two Breakthrough Publications in Medical Journals, EMBO and Cancer Discovery,Supporting LIXTE’s Clinical Trial Program- PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- . (“LIXTE” or the “Company”) (...

 PRESS RELEASE

New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metab...

New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form -- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- . (“LIXTE” or the “Company”) ( and LIXTW), a clinical-stage pharmaceutical company, today announced online publication of new pre-clinical data in and demonstrating how the Company’s lead clinical compound, LB-100, is converted into its active form, endothall, a protein  (PP2A) inhibitor that has been found to be effecti...

 PRESS RELEASE

LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Sit...

LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer -- Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100  in Combination with GSK’s Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (“LIXTE” or the “Company”) ( and LIXTW), a clinical stage pharmaceutical company, today announced it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Company’s proprietary...

 PRESS RELEASE

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Dire...

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PASADENA, CALIF., Feb. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 434,784 shares of the Company’s common stock at a purchase price of $2.415 per share. In addition, in a concurrent private p...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch